Find and compare companies providing Drug Substance (CDMO/CRO) services for:
Peptides
Filters
Production region
Production scale
Qualifications
CDMO-CRO
Specialized in complex product development and manufacturing.
High-quality standards with a focus on customer-specific needs.
Agile and innovative approach to CDMO services.
All certificates
Replies quickly
CDMO-CRO
Plants in:
Established in: 2023
Production scale:
small
medium
large
Employees: 1000+
Expertise in Conventional, Complex, and Niche Chemistries
End-to-end Support from early development to Commercial Phases
Comprehensive Analytical Support Facilities
All certificates
Replies quickly
Follow us
CDMO-CRO
Plants in:
Established in: 2008
Production scale:
large
small
medium
Employees: 4.000
With 14 production sites in Europe and the USA
7 Development Centers of Excellence covering all dosage forms
13 locations with Technology Services on site for seamless Tech Transfer and product Life-Cycle Management
All certificates
Replies quickly
CDMO-CRO
Plants in:
Established in: 1951
Production scale:
medium
Employees: 455+
Largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market.
FDA approved european manufcaturing facilities
Export APIs to more than 60 countries worldwide
All certificates
Replies quickly
Plants in:
Established in: 2016
Production scale:
small
medium
large
Employees: 200
PFAS-Free Peptides
Certified Quality & Sustainability with ISO 9000 certification and RSPO audited supplier & GMP
Specialized in APIs & Pharmaceutical Intermediates
All certificates
Replies quickly
CDMO-CRO
Plants in:
Established in: 1989
Production scale:
large
Employees: 5000+
6 production facilities approved by USFDA, AGES-Austria, PMDA, WHO
R&D Centers with capabilities of ANDAs, DMFs and NDDS
462+ patents filed for drug substances and polymorphs
All certificates
Replies quickly
CDMO-CRO
Strong heritage in pharmaceutical innovation and biotechnology.
Comprehensive range of services from early development to commercial supply.
Focus on quality, reliability, and sustainability in biopharmaceutical manufacturing.
All certificates
Replies slower than most
Looking for Drug Substance (CDMO/CRO) Services?
Find a list of providers specializing in CMOs/CDMOs Services for Peptides. Navigate through our extensive selection to identify the supplier that aligns with your specific needs.
Pharmaoffer makes it easy and convenient to send inquiries at no cost. Directly connect with your chosen supplier and take the first step towards fulfilling your pharmaceutical needs easily and efficiently.
Drug Substance (CDMO/CRO)
Drug Substance CDMOs and CROs provide end-to-end solutions for pharmaceutical companies developing and manufacturing active pharmaceutical ingredients (APIs). These organizations offer critical support in R&D, process development, scale-up, and GMP manufacturing, enabling pharma and biotech companies to accelerate time-to-market while ensuring compliance with global regulatory standards.
Peptides
Peptide outsourcing focuses on synthesizing peptide drug substance using solid-phase or solution-phase methods.
A pharmaceutical CDMO develops efficient synthesis cycles, purifies the peptide to specification,
and delivers GMP batches with verified identity and purity.
Typical steps include resin loading, coupling and deprotection cycles, purification, and lyophilization or drying.
Key constraints often involve sequence length, aggregation, and tight impurity profiles.
Practical answers for buyers sourcing CDMO services for peptide drug substance manufacturing.
A peptide CDMO develops and manufactures peptide drug substance using solid-phase or solution-phase synthesis.
Services include purification, analytical characterization, and GMP manufacturing.
Most peptide CDMOs use solid-phase peptide synthesis for short to medium sequences and solution-phase for longer or complex constructs.
The method depends on sequence length, modifications, and scale.
Include sequence, length, modifications, desired purity, batch size, and target markets.
Add information about salt form, counterions, and analytical method preferences.
Purity control relies on high-performance liquid chromatography, mass spectrometry, and stringent deprotection protocols.
Ask about deletion sequences and oxidation control strategies.
Many do, including PEGylation, lipidation, or other conjugations.
Confirm experience with your modification type and required analytics.
Peptide batches can range from grams for early-stage programs to multi-kilogram GMP campaigns.
Provide forecasted demand to match reactor and purification capacity.
Confirm GMP inspections, validated cleaning procedures, and impurity control documentation.
Ensure the facility is experienced with peptide-specific analytical testing.
Yes, many peptide CDMOs provide clinical and commercial supply.
Verify timelines and stability study capability for your trial phase.
Pitfalls include underestimating sequence complexity, inadequate impurity specifications, and unclear salt form requirements.
Early alignment on analytics reduces rework.
Some CDMOs offer lyophilization or drying services for peptide drug substance.
Confirm capacity and cycle development support if needed.
Analytical methods are critical for confirming sequence, purity, and identity.
In-house capabilities often reduce turnaround time for release testing.
Yes, peptide CDMOs optimize synthesis cycles, resin loading, and purification to improve yield.
Share lab-scale data to accelerate scale-up.
CDMOs often support drug master file content, batch records, and analytical data packages.
Confirm the exact documentation scope in your RFQ.
Use filters for region, stage, and services, then check experience with similar sequence length and modifications.
Shortlist partners with strong purification and analytics.
What is peptide outsourcing (CDMO)?
When to choose a CDMO for peptides
Common buyer requirements
Peptide CDMO services FAQ
What does a peptide CDMO do for drug substance?
What synthesis methods are common for peptide CDMO services?
What should I include in a peptide CDMO RFQ?
How do peptide CDMOs control purity and impurities?
Do peptide CDMOs handle modified or conjugated peptides?
What batch sizes are typical for peptide CDMO manufacturing?
How do I evaluate GMP readiness for peptide drug substance?
Are peptide CDMO services suitable for clinical trial supply?
What are common pitfalls in peptide CDMO outsourcing?
Do peptide CDMOs support lyophilization?
How important are analytical methods for peptide CDMO manufacturing?
Can a peptide CDMO help with process development and scale-up?
What regulatory documentation is typical for peptide drug substance?
How do I shortlist peptide CDMO companies in this directory?
